Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Magnetic resonance spectroscopy in Alzheimer’s disease
Authors Graff-Radford J, Kantarci K
Received 5 March 2013
Accepted for publication 3 April 2013
Published 16 May 2013 Volume 2013:9 Pages 687—696
DOI https://doi.org/10.2147/NDT.S35440
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Jonathan Graff-Radford,1 Kejal Kantarci2
1Department of Neurology, 2Department of Radiology, Mayo Clinic, Rochester, MN, USA
Abstract: Aging is the primary risk factor for dementia. With increasing life expectancy and aging populations worldwide, dementia is becoming one of the significant public health problems of the century. The most common pathology underlying dementia in older adults is Alzheimer’s disease. Proton magnetic resonance spectroscopy (MRS) may provide a window into the biochemical changes associated with the loss of neuronal integrity and other neurodegenerative pathology that involve the brain before the manifestations of cognitive impairment in patients who are at risk for Alzheimer’s disease. This review focuses on proton MRS studies in normal aging, mild cognitive impairment, and dementia, and how proton MRS metabolite levels may be potential biomarkers for early diagnosis of dementia-related pathologic changes in the brain.
Keywords: Alzheimer’s disease, magnetic resonance spectroscopy, mild cognitive impairment
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.